Finoriq research workspace
Q32 Bio Inc. (QTTB) SEC Filings & Filing Highlights
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy. Review QTTB SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
- Company
- Q32 Bio Inc. (QTTB)
- Ticker
- QTTB
- Market Cap
- $253.5M
- Latest Price
- $14.95
- Industry
- Biotech & Pharma
Q32 Bio Inc. (QTTB) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Q32 Bio Inc. (QTTB).
| Event | Form | Date |
|---|---|---|
| Proposal No. 1 - Election of Class II DirectorsDuring the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Q32 Bio Inc. (the “Company”), the Company’s stockholders considere... | 8-K5.07 | 2026-06-16 |
| Q32 Bio Announces $55 Million Private Placement FinancingQ32 Bio Announces $55 Million Private Placement Financing | 8-K8.01 | 2026-05-27 |
| Securities Purchase AgreementOn May 26, 2026, Q32 Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with selec... | 8-K1.01 | 2026-05-27 |
| Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update | 8-K2.02 | 2026-05-05 |
| Q32 Bio Inc.: Corporate updateAs previously disclosed, on March 27, 2026, Q32 Bio Inc. (the “Company”) entered into a Controlled Equity OfferingSM Sales Agreement (the “... | 8-K8.01 | 2026-04-24 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.